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Abstract 
MicroRNAs (miRNAs) are small non coding RNA molecules that negatively regulate 
gene expression at the post-transcriptional level. Currently, there are 939 mature human 
miRNA sequences listed in the Sanger updated miRNA registry. There are 
approximately 1500 predicted miRNAs in the human genome that may regulate the 
expression of one-third of our genes. By controlling the accumulation of the target 
protein(s) in cells, these regulatory RNA molecules participate in key functions in many 
physiological networks and their deregulation has been implicated in the pathogenesis 
of serious human disorders, such as cancer and infection. The implication of miRNAs in 
immune-mediated disorders such as rheumatoid arthritis (RA) has recently emerged 
suggesting that miRNA based therapeutic approaches may have a promising potential 
in these diseases. Here, we provide an overview of the state-of-the-art on miRNAs in 
RA, focusing on both systemic and local features of the pathology.  
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Introduction 
Over the last decade, it has become clear that small ribonucleic acids (RNAs) are 
important components of the cellular gene regulatory networks. Among these, 
micro(mi)RNAs are a family of endogenous, small, noncoding single-stranded RNA of 
approximately 22 nucleotides in length that act as posttranscriptional gene regulatory 
elements. Currently, miRNAs have been found in virtually all species (animals, plants, 
and viruses) and there are over 900 mature human miRNA sequences listed in the 
Sanger updated miRNA registry (miRBase 15). There are approximately 1500 predicted 
miRNAs in the human genome that may regulate the expression of up to one-third of 
our genes. By controlling the accumulation of the target protein(s) in cells, these 
regulatory RNA molecules participate in key functions in many physiological networks 
and their deregulation has been implicated in the pathogenesis of serious human 
disorders, such as cancer and infection. The implication of miRNAs in immune-
mediated disorders has emerged in 2007 with the identification of auto-antibodies 
directed against one component of the RNAi pathway, argonaute 2, in the serum of 
patients suffering from Sjögren's syndrome (SjS), systemic lupus erythematosus (SLE), 
and rheumatoid arthritis (RA). Since then, many more publications reinforced the 
promise that miRNAs possess great potential both at fundamental and clinical levels as 
a novel class of therapeutic targets, tool for molecular intervention, and diagnosis 
biomarkers in such diseases. Here we provide an overview of the current state-of-the-art 
on miRNAs in RA.  
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 MicroRNA biogenesis and function 
In human, the majority of mature miRNAs (70%) are transcribed from introns and/or 
exons, and approximately 30% are located in intergenic regions. Long primary 
transcripts, namely primary miRNA or pri-miRNA (Figure 1), are transcribed by RNA 
polymerase II from mono- or poly-cistronic miRNA genes. A single pri-miRNA may 
range from approximately 200 nucleotides (nt) to several kilobases (kb) in length and 
have both a 5’ 7-methylguanosine (m7) caps and a 3’ poly(A) tail. Pri-miRNAs fold into 
hairpin structures containing imperfectly base-paired stems and the mature miRNA 
sequences are characteristically localized to regions of imperfect stem-loop sequences. In 
the nucleus, pri-miRNAs are processed by the RNase III DROSHA and its cofactor 
DGRC8 (Digeorge syndrome critical region gene 8), into 70-100 nt-long hairpin with a 
monophosphate at the 5’ terminus and a 2-nt overhang with a hydroxyl group at the 3’ 
terminus called pre-miRNA. Next, the pre-miRNAs are exported from the nucleus into 
the cytoplasm as complexes with Exportin-5 and RAN-GTP cofactor. Once in the 
cytoplasm, the pre-miRNA is further digested by the RNase III enzyme Dicer along with 
its partner protein TRBP (trans-activator RNA binding protein) to produce the mature 
miRNA duplex of 20-22 nt. The miRNA “guide” strand, currently identified as the 
5’terminus that is energetically less stable, is then selected for incorporation into the 
RISC (RNA-induced silencing complex), while the “passenger” strand is released and 
degraded. Occasionally, both arms of the pre-miRNA hairpin give rise to mature 
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miRNAs as evidenced by recent data from the deep sequencing, suggesting a role 
played by both strands. The actions of the miRNA guide strand are mediated by the 
catalytic component of the ribonucleoprotein (miRNP) RISC complex formed by a 
member of the Argonaute family (Ago). The miRNA-RISC complex interacts with the 
complementary 3’- or 5’- untranslated region (UTR) of target messenger (m)RNAs 
through imperfect matching. Recent publications predict that miRNAs might also target 
the promoter and CDS region, suggesting that miRNAs might also play a transcriptional 
regulatory role. Any position on a target mRNA downstream of initiation is sufficient 
for a miRNA to exert repression of translation, the most stringent requirement being a 
contiguous and perfect base pairing of the miRNA nucleotides 2–8, representing the 
“seed” region, which nucleates the interaction. Another rule is the presence of 
mismatches (bulges) in the central region of the miRNA–mRNA duplex, precluding the 
Ago-mediated cleavage of mRNA. In the case of perfect complementary between a 
miRNA and its target, the mRNA is degraded through the RNA silencing mechanism in 
a process distinct from miRNA-mediated translation repression.  
The function of most of the mammalian miRNAs has yet to be determined but it appears 
that deregulation of this genetic regulatory network can be important in the 
pathogenesis of serious human disorders, such as cancer and infection, and might 
therefore have a great therapeutic implication.  
 
miRNAs and the immune system 
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The first evidences show that miRNAs represent an archaic immune system protecting 
plants, insects, nematodes and eukaryotes from viral infection; and growing literature 
identified several miRNAs as key regulators of the hematopoietic lineage differentiation 
and stability. Expression of miRNAs is initially controlled at the transcriptional level by 
transcription factors that regulate the production of miRNA-containing primary 
transcripts in specific cell types during development or in response to different 
environmental cues. There is evidence that some of these processes are influenced by 
immune challenges, inflammation or other forms of cellular stress. Examples of miRNA-
mediated regulation of immune cells are reported in granulopoiesis, T and B cell 
development and maturation, in innate immunity, as well as in the adaptive immune 
response. Thanks to the identification of their target genes, miRNAs have been shown to 
regulate antigen-presentation, Toll-like receptor (TLR) signalling cascade and cytokine 
production, immunoglobulin class-switch recombination in B cells, and T cell receptor 
signaling, representing thus a negative feedback mechanism that attenuates the T-cell 
activation and innate immune responses, and limits excessive inflammatory response. 
Overall studies show that miR-181, miR-223 and miR-142s are preferentially expressed 
in hematopoietic tissues.  
In vitro, miR-223 has been shown to regulate human granulopoiesis [1]. In human 
myeloid lineages, miR-146a, miR-155 and miR-132 are up-regulatedin response to Toll-
like receptor (TLR) signalling and pro-inflammatory cytokines, while miR-125b is down-
regulated [2]. In response to LPS, miR-181c and let-7e are up-regulated through the 
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protein kinase Akt1, while miR-125b and miR-155 are down-regulated [3]. Recently, 
using microarray technologies, Luers and co-workers have identified a miRNA-based 
expression profile in human primary macrophages, and validated the expression levels 
for 8 out of 119 miRNAs [4].  
During B cell differentiation, a distinct miRNA expression profile is displayed by each 
B-cell subpopulation, with miR-223 highly expressed in naïve and memory B cells and 
miR-125b up-regulated in GC lymphocytes [5]. However, miR-223 expression is mostly 
confined to bone marrow and myeloid (Gr-1+ and Mac-1+) lineages. miR-181a is 
strongly expressed in thymus, decreased during B cell development from the pro-B to 
the pre-B cell stage, and increased again from pre-B to mature B cell [6]. Ectopic 
expression of miR-181 or miR-223 in Lin- hematopoietic progenitors isolated from 
mouse bone marrow resulted in a doubling of cells in the B- and T-lymphoid lineage 
respectively [7]. miR-150 is expressed at low levels in B-cell progenitors and its up-
regulation blocks B-cell differentiation. Human B-cell malignancies are frequently 
associated with high expression levels of miR-155 that impairs germinal center 
responses [8] and immunoglobulin class switch through deregulation of the AID 
(activation-induced cytidine deaminase) expression [9]. During B-cell development, 
miR-17-92 is highly expressed in progenitors, enhancing B-cell proliferation and 
survival through the silencing of the anti-apoptotic protein Bim, while the expression 
levels of the cluster decrease 2- to 3-fold upon maturation [10].  
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miR-181a has also been shown to modulate T cell receptor (TCR) signalling through 
multiple target genes, mainly encoding phosphatases such as SHP2, PTPN22, DUSP5, 
DUSP6, that act as negative regulators of T cell activation in response to antigens [11].  
Ectopic expression of miR-17-92 cluster results in an expansion of both CD4 and CD8 T 
cells [10]. Although similarities exist between the miRNA profiles of natural T 
regulatory (Treg) cells and activated CD4 T cells, some miRNAs appear very specifically 
differentially expressed, such as miR-233 and miR-146 that are over-expressed in Treg 
but not in activated T cells, while miR-20b, -31, -99a, -100, -125b, -151, -335 and -365 have 
lower expression [12]. miR-155 is involved in the Treg homeostasis as its expression is 
directly regulated by Foxp3. Its up-regulation during thymic differentiation is important 
for increased Treg sensitivity to their principal growth factor, IL-2, and by targeting 
SOCS1, a negative regulator of IL-2R signalling, miR-155 regulates Treg survival [13]. 
Finally, miR-326 regulates Th-17 differentiation by targeting Ets-1 and its in vivo 
silencing results in fewer Th-17 cells and mild autoimmunity [14].  
 
Emerging roles for miRNAs in autoimmunity. 
 Hematopoietic-specific miRNA expression patterns have been identified in 
physiological and pathological conditions and first evidences of an implication of 
miRNAs in immune-mediated disorders has emerged a decade ago. Thus, the 
exploration of the roles of miRNAs in the context of autoimmunity is only being started 
and it is not surprising that recent studies reveal links between miRNA functions and 
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autoimmunity. The first miRNA-deficient animals generated were the miR-155 KO mice 
[8]. They displayed severe immunodeficiencies, particularly impaired B-cell responses 
and skewed Th2 cell responses. Down-regulation of miR-155 does not significantly 
compromise Treg function in vitro or in vivo, although miR-155-deficient mice have 
impaired development of Treg lineage. Mice with increased expression of miR-17-92 in 
lymphocytes developed autoimmune disease resembling to SLE [10]. Recently, Du and 
co-workers identified a Th17 cell-associated miRNA, miR-326, whose expression is 
highly correlated with disease severity in patients with MS and the corresponding 
mouse EAE model. Finally, crossing the FoxP3-GFP-hCre transgenic (Tg) mice with the 
conditional Dicer knockout mice (Dicer lox/lox) to selectively inactivate miRNAs 
generation in Treg cells, Zhou and collaborators showed that the Treg cells developed 
normally in the thymus, but changed in their differentiation and functional capacities in 
the periphery. The Dicer-deficient Treg cells failed to remain stable and altered 
expression of multiple genes and proteins associated with the Treg cell fingerprint, 
including FoxP3, was observed. In addition to their instability, mice rapidly develop 
spontaneous systemic autoimmune disease similar to the disease observed in Treg cell–
deficient FoxP3 KO mice [15]. Liston et al. also found that Treg cell–mediated tolerance 
is critically dependent on miRNA pathway as miRNA depletion within the Treg cell 
lineage resulted in fatal autoimmunity indistinguishable from Treg cell–deficient mice 
[16]. Overall, the ability of miRNAs to modulate both innate and adaptive immunity, 
and both T and B cell biology, strongly suggested that miRNAs will represent an 
 9 
additional class of genes involved in the development of autoimmune disorders, that 
might represent novel innovative targets for molecular intervention. 
 
The first clinical data linking RNAi pathways to autoimmunity showed that specific 
anti-SU auto-antibodies detected in the serum of patients suffering from Sjögren's 
syndrome (SjS), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA), are 
directed towards Argonaute 2 and other components of the GW/P bodies, a unique 
cytoplasmic structure involved in mRNA processing and RNAi [17]. In 2008, using a 
genome-wide disease phenocode analysis, Glinsky determined relationships between 
disease-linked SNPs, miRNAs and mRNAs expression patterns in PBMCs of 16 common 
human disorders, and identified components of the nuclear import and inflammasome 
pathways to be associated with human genotypes of RA and Crohn’s disease 
populations [18]. Since then, the list of miRNAs deregulated in autoimmune disorders 
and shown to be involved in disease pathogenesis is constantly implemented (Table 1). 
  
miRNAs in rheumatoid arthritis. 
Rheumatoid arthritis (RA) is a chronic inflammatory, autoimmune disorder, primarily 
affecting the articular structures and synovial membranes of the multiple joints. Recent 
studies have uncovered dysregulated miRNA expression in RA patients, suggesting that 
abnormalities in miRNA expression may contribute to the molecular mechanisms of the 
disease. In the following sections, we will overview the current data on differential 
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miRNAs expression in RA, both in the afflicted joints and the circulation (Table 2). 
 
miR-15/16 
 Using the autoantibody-mediated arthritis model, Nagata and colleagues showed that 
the expression levels of miR-15a are lower in the synovium of diseased mice than in 
healthy controls [19]. Knowing that miR-15a induces cell apoptosis by negatively 
regulating the expression of Bcl-2 [20], they transiently over-expressed miR-15a into the 
synvoium of arthritic mice thanks to the intra-articular electrotransfer of miR-15a-
atelocollagen complexes. They showed a decreased Bcl-2 protein expression and 
increased expression of caspase 3, as compared with that the control group. 
Unfortunately, no data on the clinical effect was reported in this study. MiR-15a/16-1 
and miR-15b/16-2 clusters are highly conserved among mammalian species [21] and 
have been shown to play very important roles in regulating cell proliferation and 
apoptosis by targeting cell cycle proteins and the anti-apoptotic genes (Table 2). Several 
groups evidenced dysregulated expression of miR-15/16 in various lymphoid and 
myeloid malignancies, further emphasizing their important roles in growth signaling 
networks. Interestingly, Pauley and colleagues showed that expression levels of miR-16 
are increased in PBMC isolated from RA patients, compared with healthy donors, and 
are correlated with disease activity, suggesting that miR-16 might be used as biomarker 
of disease activity [22]. This observation was confirmed by the recent study from Murata 
et al [23] showing a significant correlation of plasma miR-16 with DAS28. Moreover, 
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synovial fluid concentrations of miR-16 are significantly higher than those of OA and of 
RA plasma, and mainly reflect secretions by synovial tissues. Interestingly, miR-16 
levels are lower in OA than in healthy donors. From other work, miR-16 is known to be 
expressed by human primary macrophages [4]. Finally, mice transgenic for the hTNF 
gene but lacking the 3’UTR that contains sequences for the ARE binding protein TTP 
and miR-16 overexpress TNF-α protein and develop spontaneous severe arthritis 
syndrome because of impaired regulation of TNF biosynthesis [24]. 
 
 miR-124a 
Recently published profiling data from miRNA expression in RASF versus OASF 
revealed several novel differentially expressed miRNAs. Particularly, miR-124a is down-
regulated in RASF as compared with OASF, and its enforced expression in RASF 
suppresses their proliferation [25]. The authors showed that miR-124a targets the 3’UTR 
of CDK-2 and MCP-1 mRNAs and decreases their protein levels. Using reporter gene 
analyses, IB appeared to be another target gene for miR-124a, suggesting its 
involvement in the fine-tuning of NFB-mediated gene expression [26]. miR-124a has 
been identified as specifically expressed in the pancreas and brain, participating to 
metabolic regulation [27, 28]. Depending on the malignancy studied, miR-124a is either 
a tumor suppressive miRNA or a metastasis-associated miRNA. 
 
miR-132 
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In RA and OA, synovial fluid concentrations of miR-132 were significantly lower than 
their plasma concentrations, and plasma miR-132 were significantly lower than that of 
healthy donors [23]. These authors also showed that plasma miR-132 well differentiated 
healthy from patients with RA or OA, while synovial fluid miR-132 differentiated RA 
from OA patients, suggesting that detection of miR-132 expression levels might be used 
as diagnosis marker. These data are in contradiction with the report from Pauley 
showing that PBMC isolated from RA blood display increased expression of miR-132 
compared with healthy controls [22]. miR-132 has been mainly studied in brain and 
neurotransmission, but it also plays anti-inflammatory functions [29]. Its expression in 
monocytes and role in the regulation of antiviral immunity has been recently reported 
[30]. 
 
miR-146a 
In five studies, miR-146 is shown up-regulated in all RA samples investigated. In four of 
them, an increased basal expression of miR-146a was reported in RASF compared with 
OASF [31, 32] and RASF are shown to be more sensitive than OASF to LPS- or IL-1β‐
induced miR-146a expression. In two out of these 5 studies, 2 groups also quantified 
miR-146a locally, either directly within the synovial fluid [23] or in CD4+ T cells isolated 
from synovial fluid [33], and found higher concentrations in RA than in OA, correlated 
with disease activity. Finally, in three of these studies, miR-146 is up-regulated in the 
circulation of RA patients compared with healthy donors; data were generated either 
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from the plasma [23], or from PBMC [22] and CD4+ T cells isolated from the blood of 
RA patients. As mentioned by Murata et al., the plasma levels of miR-146a were 
comparable between RA and OA, and Pauley found that increased miR-146a expression 
levels correlated with active disease in RA patients.  
It has been previously reported that miR-146a/b is induced in response to a variety of 
microbial components and pro-inflammatory cytokines, such as LPS, CpG, IFN-α and 
TNF-α [2]. Conversely, ectopic expression of miR-146a in PBMCs enhances the function 
of Th1 cells and induces the expression of TNF-α, MCP-1, NF-κB p65 [34]. In RA, Li et al. 
showed that the level of miR-146a expression is positively correlated with levels of TNF-
α. Induction of miR-146a expression is regulated by NF-B and miR-146a targets TNF 
receptor–associated factor 6 (TRAF6), IL-1 receptor–associated kinase 1 (IRAK1) and 
IRAK2, FADD, IRF-5, Stat-1, and PTC1 genes [35-38]. Thus, miR-146 is among the genes 
playing a role in the fine-tuning of innate immune responses through negative feedback 
loops on genes induced by inflammatory cascades. Despite the increased expression of 
miR-146a in RA PBMC, TRAF6 and IRAK-1 are equally expressed in PBMC isolated 
from both RA patients and healthy controls [22]. Furthermore, enforced expression of 
miR-146a impairs both activator protein 1 (AP-1) activity and interleukin-2 (IL-2) 
production [35], and Fas associated factor 1 (FAF1) [33], thus suggesting a role in the 
modulation of TCR engagement and T cell apoptosis. While miR-146a levels are low in 
monocytes and non detectable in neutrophiles, they are constitutive high in langerhans 
cells, in which it regulates cell sensitivity to inappropriate TLR2 activation by 
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commensal bacteria [39]. Finally, it has been shown that ectopic expression of miR-146a 
in primary human fibroblasts suppresses IL-6 and IL-8 secretion through decreased 
IRAK1, suggesting that miR-146a might be part of a compensatory network aiming at 
restraining inflammation [40]. 
  
miR-155 
The first miRNA profiling experiment performed in TNF-stimulated RA synovial 
fibroblasts (RASF) with the intention to mimick inflammatory conditions in the RA joint, 
revealed significant up-regulation of miR-155 [32]. Stanczyk and colleagues showed a 
marked up-regulation (8-fold) of miR-155 in RASF compared to synovial fibroblasts 
isolated from OA patients, as well as in the whole synovial tissue of RA patients. 
Interestingly, Murata and coworkers showed that miR-155 is secreted by synovial 
tissues in the synovial fluid, and confirmed that synovial fluid concentrations of miR-
155 are higher in RA than those in OA [23]. In the periphery, miR-155 is up-regulated in 
both plasma and PBMC from RA patients compared to heathly donors (1.8 to 2.6 fold) 
[22, 23]. Moreover, compared with monocytes from RA PBMC, RA synovial fluid 
monocytes displayed higher levels of miR-155 [32]. Finally the functional analysis 
indicated the involvement of miR-155 in the control of expression of MMP-3 and MMP-1 
under basal as well as inflammatory conditions. Numerous target genes have been 
identified for miR-155, such as c-Maf, Bach1, PU.1, c/EBP and SHIP1. Recently, McCoy 
C et al. [41] showed that, in bone marrow-derived macrophages, the anti-inflammatory 
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cytokine IL-10 inhibits the LPS-induced transcription of miR-155 from the BIC gene, in a 
STAT3 dependent manner, leading to an increased expression of SHIP1, a miR-155 
target gene. 
  
miR-223 
As for other miRNAs investigated by Murata and colleagues, concentrations of miR-223 
in the synovial fluid are lower than those in plasma, for both RA and OA patients, and 
are mainly due to miR-223 secretion by MNC infiltrating inflamed joints [42]. Indeed, 
miR-223 is rarely secreted by RA-FLS and synovial tissues. Interestingly, miR-223 levels 
were higher in RA samples than in OA, and inversely correlated with tender joint count. 
Fulci and coworkers showed that miR-223 is the only miRNA that is markedly up-
regulated in peripheral T-lymphocytes from RA patients compared with healthy donors, 
mostly in naive CD4+ T lymphocytes [42]. An up-regulation of miR-223 in leukemia is 
widely reported in the literature. Serum miR-223 has been also proposed as a potential 
biomarker for sepsis [43]. miR-223 regulates glucose metabolism [44], and 
granulopoiesis by targeting E2F1 and CEBPα [1]. 
 
miR-346 
Alsaleh and coworkers described another miRNA to be induced by LPS and in turn to 
counteract the stimulatory effect of LPS on the IL-18 production [45]. This study 
demonstrated that miR-346 indirectly impacts on IL-18 release by inhibiting LPS-
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induced Bruton’s tyrosine kinase expression in RASF. A target sequence for miR-346 
was found in the 5'UTR of RIP140 mRNA (receptor-interacting protein 140), suggesting 
a regulatory role in hormonal and metabolic processes [46]. 
 
Finally, miR-363 and miR-498 are down-regulated in CD4+ T cells isolated from RA 
synovial fluid, as compared to normal peripheral blood CD4+ T cells, respectively [33]. 
 
Conclusion  
Identification of biological markers of disease is a major area of research, especially in RA. 
Due to the simplicity of getting a blood sample, easily testable, biomarkers found in blood 
or serum would have great potential for clinical application. Mitchell and co-workers 
showed that microRNAs are present in the blood and serum of healthy donors in 
remarkably stable forms [47]. They are well protected from RNases and remain stable 
after being subjected to harsh conditions. The progression of pregnancy has also been 
correlated with placental-associated circulating miRNAs. Such peripheral blood-based 
miRNA signatures are due to the presence of circulating microparticules and exosomes, 
as it was demonstrated in the plasma and sera of normal subjects and ovarian cancer-
bearing patients. The majority of these microvesicles were shown to derive from 
peripheral blood platelets and mononuclear phagocytes [48] in healthy donors, and from 
tumor cells shedding into the blood stream of patients with ovarian cancer [47]. From the 
above cited works, three studies confirmed that, miR-16, miR-132, miR-146a, miR-155, 
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and miR-223 are up-regulated in RA circulation compared to controls. Although most of 
these miRNAs are also deregulated in other immune-mediated disorders and cancers, the 
definition of a blood-based miRNA signature containing these miRNAs, and others to be 
yet identified, might serve as biomarker for RA diagnosis in a close future.  
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Table 1: miRNAs involved in autoimmune diseases. 
 
Up-regulated Down-regulated Associated References 
 miRNA miRNA  Diseases 
SLE miR-21, miR-61, miR-78, miR-
142-3p, miR-189 miR-198, miR-
298, miR-299-3p, miR-342, miR-
371-5p, miR-423-5p, miR-638, 
miR-663 
miR-146, miR-17-5p, miR-
112, miR-141, miR-184, miR-
196a, miR-383, miR-409-3p,  
miR-146a 
[38, 49, 50] 
 
MS miR-493, miR-599, miR-326, 
miR-34a, miR-155 , miR-326 
miR-18b [14, 51, 52] 
Psoriasis miR-146a, miR-203, miR-221, 
miR-205, miR-21 
 [53, 54] 
RA miR-16, miR-132 miR-146a, 
miR-155, miR-203 miR-223, 
miR-346, 
miR-124a, miR-15a, miR-498 
miR-363 
[19, 22, 23, 25, 32, 33, 
42, 45] 
Abbrevations: SLE, Systemic lupus erythematosus; MS, Multiple sclerosis; RA, 
Rheumatoid arthritis. 
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Table 2: Validated targets and functions of microRNAs dysregulated in rheumatoid 
arthritis. 
 
  
miRNA Targets 
 
Function 
 
Reference 
Mir-15/miR-16 BCL2, DLK1, PDCD4,  
TIA1, RASSF5, Bim-1, 
Cyclin D1, cyclin E1, MYB 
Apoptosis 
Proliferation 
[20, 55-60] 
miR-124a CDK-2, MCP-1, IB Apoptosis 
Inflammation 
[25, 26] 
miR-146a IRAK1, IRAK2, TRAF6, 
FADD, IRF-5, STAT1, 
PTC1, FAF-1 
Inflammation 
Apoptosis 
[2, 33, 35-38] 
MMP-1, MMP-3, c-Maf, 
Bach-1, PU.1, CEBP, 
SHIP-1, ZIC3, HIVEP2, 
ZNF652, ARID2,  SMAD5 
Remodeling 
inflammation 
Antiviral immunity 
[32, 41] miR-155 
E2F1, CEBP Granulopoiesis miR-223 
Glucose metabolism 
[1, 44] 
MiR-346 Btk, RIP140 Inflammation 
Hormonal, metabolism 
processes 
[45, 46] 
 28 
miR-132 
miR-363 
mir-498 
ND Neurotransmisson 
Inflammation 
[29, 30, 33] 
This table lists all the miRNAs that have been deregulated in rheumatoid arthritis, as well 
as their validated targets and functions.  
Abbrevations: BCL2, B-cell CLL/lymphoma 2; DLK1, delta-like 1 homolog; PDCD4, 
programmed cell death 4; TIA1, T-cell-restricted intracellular antigen-1; RASSF5, Ras 
association domain family member 5; Bim-1, BCL2-like 11; MYB, v-myb myeloblastosis 
viral oncogene homolog; CDK2, cyclin-dependent kinase 2; MCP-1, monocyte 
chemoattractant protein; IB, nuclear factor of kappa light polypeptide gene enhancer in 
B-cells inhibitor, zeta;  IRAK, IL-1 receptor activated kinase; TRAF, TNF receptor-
associated factor ; STAT, signal transducer and activator of transcription; IRF, Interferon 
regulatory factor; IKK, IkappaB kinase; FADD, Fas-associated via death domain; PTC1, 
patched homolog 1; FAF1, Fas (TNFRSF6) associated factor 1; MMP, matrix 
metallopeptidase; C-Maf, v-maf musculoaponeurotic fibrosarcoma oncogene homolog ; 
Bach-1, BTB and CNC homology 1, basic leucine zipper transcription factor 1; PU.1, 
spleen focus forming virus (SFFV) proviral integration oncogene spi1; CEBP, 
CCAAT/enhancer binding protein; SHIP-1, inositol polyphosphate-5-phosphatase; ZIC3, 
Zic family member 3; HIVEP2, human immunodeficiency virus type I enhancer binding 
protein 2; ZNF652, zinc finger protein 652; ARID2, AT rich interactive domain 2 ; SMAD5, 
; E2F1, E2F transcription factor 1; Btk, Bruton agammaglobulinemia tyrosine kinase; 
RIP140, nuclear receptor interacting protein 1.  
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Table 3: Tissue distribution of miRNAs dysregulated in RA. 
 
 BLOOD JOINT 
 PBMC Serum/plasma CD4+ ST RA-FLS SF CD4+ 
miR-15a    X    
miR-16 X X  X  X  
miR-124a     X   
Mir-132 X X  X  X  
Mir-146a X X X  X X X 
Mir-155 X X  X X X  
Mir223  X  X X X  
Mir346     X   
Mir-363 X      X 
Mir-498       X 
Abbrevations: PBMC, Peripheral Blood Mononuclear Cell; ST , synovial tissue; RA-FLS, 
fibroblast-like synoviocytes from RA patients; SF, synovial fluid. 
 
 
 
 
 
